A randomized feasibility trial evaluating resistance training and protein supplementation in patients with incurable gastroesophageal cancer was published 5 November 2026. The trial appears in Supportive Care in Cancer, and is indexed on PubMed and ClinicalTrials.gov.^[1] 20 participants were randomized out of 106 potentially eligible patients. This yielded a recruitment rate of 19%. The cohort included 5 female and 15 male patients, with a mean age of 65. 18 participants completed the trial, for a retention rate of 90%. The trial's primary outcome was feasibility, measured via recruitment, retention, adherence and harms. The study received funding from TrygFonden. It was conducted in line with the Declaration of Helsinki. Ethics approval was granted by the Scientific Ethics Committees for the Capital Region.